NOS2 and neoplasm: For example, administering the Toll-like receptor 7 (TLR7) agonist imiquimod requires the simultaneous inhibition of iNOS activity to promote tumor antigen-specific Th1 responses and suppress tumor growth in vivo (Ito et al., 2015).